Update on azole antifungals
- PMID: 18366001
- DOI: 10.1055/s-2008-1063858
Update on azole antifungals
Abstract
This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use. Key clinical trials are briefly discussed, and specific drug indications summarized. Fluconazole remains a valuable low-cost choice for the treatment of various fungal infections, including candidiasis and cryptococcosis. It has relatively few drug interactions and is safe but lacks activity against filamentous fungi. The use of itraconazole is historically plagued by erratic bioavailability of the oral capsule, improved with the oral solution. Drug interactions are numerous. Itraconazole exhibits significant activity against Aspergillus and the endemic fungi. Voriconazole has revolutionized the treatment of aspergillosis in severely immunocompromised patients, but its use is compromised by complicated pharmacokinetics, notable drug interactions, and relatively significant adverse events. Finally, posaconazole is the last addition to the azole armamentarium with extended antifungal spectrum, significant activity against the zygomycetes, and, apparently, optimal safety profile. Posaconazole has a significant role for the prophylaxis of invasive fungal infections in severely immunocompromised patients. Multiple daily dosing, a need for fatty foods for absorption, and absence of an intravenous formulation restrict its use to selected populations.
Similar articles
-
Posaconazole: an extended-spectrum triazole antifungal agent.Clin Ther. 2007 Sep;29(9):1862-86. doi: 10.1016/j.clinthera.2007.09.015. Clin Ther. 2007. PMID: 18035188 Review.
-
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Expert Rev Anti Infect Ther. 2009. PMID: 19803707 Review.
-
Posaconazole: a next-generation triazole antifungal.Future Microbiol. 2007 Jun;2(3):231-43. doi: 10.2217/17460913.2.3.231. Future Microbiol. 2007. PMID: 17661696
-
Posaconazole: clinical pharmacology and potential for management of fungal infections.Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. doi: 10.1586/14787210.3.4.467. Expert Rev Anti Infect Ther. 2005. PMID: 16107193 Review.
-
Triazole antifungal agents in invasive fungal infections: a comparative review.Drugs. 2011 Dec 24;71(18):2405-19. doi: 10.2165/11596540-000000000-00000. Drugs. 2011. PMID: 22141384 Review.
Cited by
-
The basic leucine zipper transcription factor MeaB is critical for biofilm formation, cell wall integrity, and virulence in Aspergillus fumigatus.mSphere. 2024 Feb 28;9(2):e0061923. doi: 10.1128/msphere.00619-23. Epub 2024 Jan 29. mSphere. 2024. PMID: 38284755 Free PMC article.
-
In Vitro and In Silico Evaluations of the Antileishmanial Activities of New Benzimidazole-Triazole Derivatives.Vet Sci. 2023 Nov 9;10(11):648. doi: 10.3390/vetsci10110648. Vet Sci. 2023. PMID: 37999471 Free PMC article.
-
Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?Antibiotics (Basel). 2022 May 12;11(5):645. doi: 10.3390/antibiotics11050645. Antibiotics (Basel). 2022. PMID: 35625289 Free PMC article. Review.
-
Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database.Front Pharmacol. 2022 Apr 28;13:891336. doi: 10.3389/fphar.2022.891336. eCollection 2022. Front Pharmacol. 2022. PMID: 35571077 Free PMC article.
-
Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications.Front Mol Biosci. 2022 Apr 25;9:864286. doi: 10.3389/fmolb.2022.864286. eCollection 2022. Front Mol Biosci. 2022. PMID: 35547394 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
